Almarai expands paediatric rheumatism care support

Almarai has signed a one-year agreement in Riyadh to provide essential medication for children living with rheumatism, widening private-sector support for families facing long-term treatment costs and limited access to specialised care.

The agreement with the Charitable Association for Rheumatism Patients is aimed at children whose health can deteriorate when diagnosis, medication and follow-up care are delayed or interrupted. The initiative is designed to improve mobility, ease pain, protect daily functioning and reduce complications linked to chronic inflammatory disease.

Childhood rheumatism, commonly associated with juvenile idiopathic arthritis and related autoimmune conditions, can affect joints, muscles, eyes and other organs. Symptoms often include swelling, stiffness, persistent pain, fatigue and restricted movement. For children, the impact can extend beyond physical discomfort, affecting school attendance, sleep, play, emotional wellbeing and family finances.

The Riyadh-based partnership places medication support at the centre of the intervention. That focus is significant because many paediatric rheumatic conditions require sustained therapy rather than short-term treatment. Interruptions can increase the risk of joint damage, growth problems, contractures and reduced quality of life. Specialist care may also involve monitoring for eye inflammation, immune complications and treatment side effects.

Almarai’s move fits within a wider pattern of corporate social responsibility activity in Saudi Arabia, where large listed companies have been under growing pressure to connect community programmes with measurable social outcomes. Healthcare, disability inclusion, food security, education and child welfare have become important areas of private-sector engagement as the kingdom expands partnerships between companies, charities and public institutions.

For Almarai, the agreement also reinforces its position as one of the region’s most visible consumer companies. Headquartered in Riyadh and listed on Tadawul, the company has built its business across dairy, juice, bakery, poultry and infant nutrition categories. Its 2025 annual figures showed sales of SAR22.065 billion, net profit of SAR2.456 billion, operating cash flow of SAR5.463 billion and capital expenditure of SAR4.385 billion, giving it the scale to support targeted community health initiatives.

Children with rheumatic disease are a relatively small but medically vulnerable patient group. Juvenile idiopathic arthritis is often described as the most common chronic inflammatory arthritis in children. Its severity varies widely: some children experience limited joint involvement, while others face systemic disease requiring advanced therapies and long-term specialist supervision.

Access to biologic medicines and disease-modifying therapies has changed outcomes for many patients, but cost, continuity and specialist availability remain concerns for families. Treatment can include anti-inflammatory drugs, corticosteroids, disease-modifying anti-rheumatic drugs, biologic agents, physiotherapy, occupational therapy and regular clinical monitoring. Early intervention is central to preventing irreversible disability.

Saudi Arabia has developed paediatric rheumatology expertise through major tertiary hospitals and specialist centres, yet charitable support remains important for families with constrained resources. Long-term childhood illness can create indirect costs, including transport to appointments, missed work by caregivers, school disruption and rehabilitation needs. These pressures are often heavier when treatment must continue for years.

The Charitable Association for Rheumatism Patients is expected to use the partnership to direct support towards children most in need of sustained medication. The stated aim is not only to reduce symptoms but to help children maintain independence, physical activity and social participation. That approach reflects a growing understanding that chronic disease care for children must consider education, development and family stability, not only clinical treatment.

Musculoskeletal conditions are among the world’s largest contributors to disability, affecting people across age groups. Childhood autoimmune inflammatory conditions can shape development and long-term health if not properly managed. For paediatric patients, the consequences of delayed care can appear over time through reduced mobility, impaired growth, pain-related anxiety and avoidable dependence on caregivers.